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In recent years, there has been considerable controversy
concerning the discovery and translation into clinical
practice of the prostate-specific antigen (PSA) [1e4]. In this
brief review, I offer the relevant historical facts as I believe
them to be true.
Before the development of the PSA blood test, prostatic
acid phosphatase was the most important blood test for
prostate cancer, but it was of no value for the early
detection of prostate cancer, because serum acid phos-
phatase levels became elevated mainly in men who already
had bone metastases [5].
2. Early discovery of prostate-specific antigen
In the 1960s and 1970s, many researchers were searching
for tumor-specific antigens that might be useful as bio-
markers or targets for immunotherapy of cancer. Typical
experiments involved injecting an extract of a human tissue
or body fluid, such as a prostate tissue or seminal fluid, into
rabbits and testing the rabbit serum for antibodies against
the antigens present in the extract or fluid.
The earliest report on the properties of antigens in the
prostate was by the American urologist, Rubin Flocks, in
1960 [6,7]. In 1966, Mitsuwo Hara, a Japanese forensic
scientist, reported on and partially characterized a protein,
which he called “gamma-seminoprotein”. He suggested itsE-mail address: wcatalona@nmff.org.
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1970, Tien Shun Li and Carl Beling [9,10], conducting
research on male infertility, reported on antigens in human
semen, one of which was later shown to have the same
amino acid sequence of PSA. That same year, Richard Ablin
and coworkers reported finding two antigens that were
specific to the human prostate, one of which was distinct
from acid phosphatase [11e13]. Ablin then moved on to
pursue clinical studies attempting to induce an anti-tumor
immune response through cryoablation of the prostate
gland. In 1978, forensic scientist George Sensabaugh also
identified a protein in semen that was similar to one of Li’s
antigens and was later shown to have the same amino acid
sequence as PSA [14,15].
3. Purification, characterization, and
development of PSA as a biomarker blood test
for prostate cancer
In my opinion, the real credit for the discovery of PSA as a
clinically useful biomarker for prostate cancer and for
translating it into clinical use belongs to T. Ming Chu and his
research group, most notably Ming C. Wang, who conducted
a remarkable focused series of studies over several years at
the Roswell Park Memorial Institute [1,2]. In a landmark
study in 1979, Wang and coworkers purified and charac-
terized PSA and suggested potential clinical applications as
a biomarker for prostate cancer [16]. This set the stage for
the development of a PSA blood test, which was subse-
quently achieved in steps by Lawrence D. Papsidero [17]
and Manabu Kuriyama [18], Wang and their coworkers in
Chu’s research group. They developed a sensitive ELISAn and hosting by Elsevier (Singapore) Pte Ltd. This is an open access
censes/by-nc-nd/4.0/).
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performed early studies exploring the potential clinical
uses of PSA as a biomarker in prostatic diseases. Ultimately,
T. Ming Chu and Roswell Park Memorial Institute received
the patent for the discovery of “purified human prostate
antigen” in 1984, and Chu has been honored on many oc-
casions as the discoverer of PSA [19].
What emerged from the early clinical studies by Chu’s
group, and was further validated by Thomas A. Stamey [20]
and others, was that PSA was clinically useful for moni-
toring the course of patients already known to have pros-
tate cancer. However, because there was overlap of serum
PSA levels between patients with prostate cancer, benign
prostatic hyperplasia, and prostatitis, and PSA levels were
sometimes “normal” or low in patients with prostate can-
cer, it was not believed that PSA could be used as a first-line
screening test for prostate cancer. Rather, physicians and
researchers were focused on finding a marker that func-
tioned like a pregnancy test, i.e., always positive when
cancer was present and always negative when cancer was
absent. Therefore, until the 1990s, PSA was largely used for
monitoring the response of prostate cancer patients to
treatment.
In the early 1990s, it was first demonstrated that the PSA
blood test could be used as a first-line screening test for
prostate cancer [21], which led to the approval of the PSA
test by the United States Food and Drug Administration
(FDA) as an aid to the early detection of prostate cancer
[22]. PSA derivatives, such as PSA velocity [23], PSA density
[24,25], and the free-to-total PSA ratio [26] (also FDA
approved) served to improve the accuracy of PSA testing.
More recently, other PSA isoforms, such as the [-2]proPSA,
have been found to be a more cancer-specific biomarker for
prostate cancer, which has led to FDA approval of the
Prostate Health Index (PHI) in 2013 [27].
4. PSA testing reduces prostate cancer-specific
mortality
During the “PSA era” in the United States, the proportion of
patients having advanced disease at diagnosis has
decreased by 80%, and the age-adjusted prostate cancer
mortality rate has decreased by more than 42% [28]. Sta-
tistical modeling studies have estimated that 45%e70% of
this mortality decrease is attributed directly to PSA
screening [29,30]. Similar trends have been observed in
countries that have adopted widespread PSA screening but
not in those that have not adopted PSA screening [31]. Two
large prospective, randomized clinical trials in Europe have
demonstrated a 21% and 44%, respectively, decrease in
prostate cancer-specific mortality associated with PSA
screening [32,33].
5. Concerns about overdiagnosis and
overtreatment
Although in recent years, population-based PSA screening
has been called into question because of concerns that the
benefits of screening may not justify the risks of over-
diagnosis and overtreatment of possibly harmless prostatecancers [34], I believe that PSA-based testing (including
PHI) is the best cancer blood test in all branches of medi-
cine, and certainly the best test currently available for
early prostate cancer detection. Although PSA-based
testing has limited specificity, I am convinced that the
intelligent use of PSA-based testing, careful selection of
patients for screening and treatment, combined with high
quality, effective treatment, could reduce the overall
prostate cancer death rate by more than half.Conflicts of interest
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